Fosun Pharma 2025 Results Highlight Innovation Pivot and Global Expansion
Key Takeaways
- Fosun Pharma reported robust 2025 financial results, driven by a record contribution from innovative drugs and successful expansion into Southeast Asian markets.
- The company's strategic focus on high-barrier biologics and R&D has solidified its transition from a generic-focused manufacturer to a global innovation leader.
Key Intelligence
Key Facts
- 1Innovative drug revenue grew by over 20% year-over-year in fiscal 2025
- 2R&D expenditure maintained at approximately 15% of pharmaceutical manufacturing revenue
- 3Hanquyou (trastuzumab biosimilar) achieved market leadership in several Southeast Asian territories
- 4Total group revenue showed double-digit growth, driven by core pharmaceutical manufacturing
- 5The company successfully expanded its commercial footprint in the Philippines and Thailand in 2025
Who's Affected
Analysis
Fosun Pharma's 2025 annual results, announced in late March 2026, underscore a transformative period for the Shanghai-based healthcare giant. The company has successfully navigated a complex global regulatory environment and domestic pricing pressures in China to emerge as a more innovation-centric entity. Central to this performance is the pharmaceutical manufacturing segment, which remains the bedrock of the group's revenue. The 2025 data reveals that innovative drug revenue now accounts for a record percentage of total sales, a clear signal that the company’s multi-year pivot away from generic-heavy portfolios is yielding tangible financial results. This shift is critical as the Chinese market continues to implement volume-based procurement (VBP) policies that squeeze margins on traditional generic medications.
A key driver of this growth has been the continued global rollout of Hanquyou (trastuzumab biosimilar) and the PD-1 inhibitor Serplulimab. These products have not only dominated their respective categories in the domestic market but have also seen significant uptake in international markets, particularly in Southeast Asia and Europe. The fact that the 2025 results were prominently featured in major regional outlets like the Manila Times and Thailand Business News highlights Fosun Pharma's successful 'Global-Local' strategy. By establishing localized commercialization teams and manufacturing hubs in these regions, the company has mitigated supply chain risks and captured emerging market demand for high-quality, affordable biologics. This regional focus is a cornerstone of their ambition to diversify revenue streams away from a single-market dependency.
A key driver of this growth has been the continued global rollout of Hanquyou (trastuzumab biosimilar) and the PD-1 inhibitor Serplulimab.
R&D investment remained a priority throughout 2025, with the company maintaining its commitment to spending approximately 15% of its pharmaceutical manufacturing revenue on research. This investment is fueling a deep pipeline of cell therapies, gene therapies, and next-generation oncology treatments. The company’s CAR-T joint venture, Fosun Kite, also reached critical milestones in 2025, expanding the indications for Yi Kai Da (axicabtagene ciloleucel) and improving patient access through innovative insurance schemes. This focus on high-barrier-to-entry therapies provides Fosun Pharma with a competitive moat against smaller biotech firms and traditional generic manufacturers who lack the capital to sustain long-term clinical development cycles.
What to Watch
Beyond pharmaceuticals, the company’s medical devices and healthcare services segments showed resilience. The medical devices division benefited from the global demand for diagnostic equipment and the localization of high-end surgical robots, such as the Da Vinci system. Meanwhile, the healthcare services segment, which includes a network of private hospitals, saw a recovery in patient volumes and operational efficiency improvements following post-pandemic restructuring. Analysts note that the integration of these segments allows Fosun Pharma to offer a comprehensive healthcare ecosystem that few of its peers can match, providing cross-selling opportunities and a more stable earnings profile.
Looking ahead to 2026, the market will be watching Fosun Pharma’s ability to manage its debt levels while continuing its aggressive R&D spending. The company has been active in optimizing its asset portfolio, divesting non-core businesses to focus on its high-growth innovative core. This disciplined capital allocation, combined with a robust pipeline of late-stage clinical assets, positions Fosun Pharma as a leading contender in the global biopharmaceutical landscape. The 2025 results are not just a reflection of past performance but a blueprint for the company’s ambition to become a top-tier global healthcare player by the end of the decade, leveraging its dual-engine growth of domestic innovation and international commercialization.
Timeline
Timeline
Regional Launch
Serplulimab receives regulatory approval in additional Southeast Asian markets.
CAR-T Milestone
Fosun Kite announces expanded indications for Yi Kai Da CAR-T therapy.
Global Partnership
Strategic agreement signed for the distribution of biosimilars in emerging markets.
Annual Results
Official release of 2025 financial performance data to global markets.
How we covered this story
Every story in our finance coverage is assembled from multiple primary sources, cross-referenced for factual consistency, and scored along three independent dimensions: sentiment, operational impact, and source-cluster confidence. Single-source rumors and unverifiable claims do not pass our editorial gate. When a story shows "Verified by N sources" with N≥2, the development is independently corroborated; when N=1, we mark it explicitly so readers can weigh the signal accordingly.
Impact scoring uses a 1-10 scale weighted toward regulatory, financial, and operational consequence rather than coverage volume. A topic that runs in every outlet but moves no real decisions ranks lower than a niche regulatory filing that reshapes how operators in the finance space have to behave. Read our full methodology for the scoring rubric, our glossary for term definitions, and our trends index for the longitudinal view across the beat.
| Signal on this page | What it tells you |
|---|---|
| Verified by N sources | Independent corroboration count. N≥2 is our confidence floor; N=1 is marked explicitly. |
| Impact score (1-10) | Regulatory + financial + operational weight. 8+ signals an experienced-operator action item. |
| Sentiment | Five-tier classification trained on labeled finance-specific corpora. |
| Timeline | Where applicable, the related-events sequence that contextualizes today's development. |